Phaseline

Companies › IDEAYA Biosciences

IDEAYA Biosciences: clinical trials, targets and expected readouts

10 active drug programs in 24 registered trials: 10 Phase 2, 10 Phase 1, 4 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Crizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 3Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma …Jan 2027
Darovasertib
Protein Kinase C (PKC) inhibitor
PRKCPhase 3Uveal MelanomaApr 2027
IDE196–Phase 2Metastatic Uveal MelanomaJan 2027
IDE397
MAT2A inhibitor
MAT2APhase 1Solid Tumor; NSCLC AdenocarcinomaJan 2027
IDE-161
PARG inhibitor
PARGPhase 1Advanced or Metastatic Solid TumorsMay 2027
IDE034
Bispecific antibody targeting B7-H3 and PTK7
B7H3, PTK7Phase 1Esophageal Squamous Cell CarcinomaJul 2027
IDE892
PRMT5 inhibitor
PRMT5Phase 1NSCLC AdenocarcinomaApr 2028
IDE161–Phase 1Small-cell Lung CancerJul 2029
IDE849
DLL3-targeted bispecific antibody
DLL3Phase 1Small-cell Lung CancerJul 2029
IDE574
KAT6/KAT7 co-inhibitor
KAT6, KAT7Phase 1CancerDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06357975CrizotinibPhase 2Advanced LymphomaOncologyDec 2026
NCT06360575CrizotinibPhase 2Advanced LymphomaOncologyDec 2026
NCT04794699IDE397Phase 1Solid TumorOncologyJan 2027
NCT05987332CrizotinibPhase 2Metastatic Uveal MelanomaOncologyJan 2027
NCT05987332IDE196Phase 2Metastatic Uveal MelanomaOncologyJan 2027
NCT03947385IDE196Phase 1Metastatic Uveal MelanomaOncologyJan 2027
NCT04439253CrizotinibPhase 2Advanced LymphomaOncologyMar 2027
NCT04439266CrizotinibPhase 2Advanced LymphomaOncologyMar 2027
NCT05907954DarovasertibPhase 2Uveal MelanomaOncologyApr 2027
NCT05787587IDE-161Phase 1Advanced or Metastatic Solid TumorsOncologyMay 2027
NCT07503808IDE034Phase 1Esophageal Squamous Cell CarcinomaOncologyJul 2027
NCT05014464CrizotinibPhase 2Non-small Cell Lung CancerOncologyAug 2027
NCT06563999CrizotinibPhase 2Lung Cancer Stage IIIOncologyNov 2027
NCT04693468CrizotinibPhase 1Advanced Malignant Solid NeoplasmOncologyDec 2027
NCT07277413IDE397Phase 1NSCLC AdenocarcinomaOncologyApr 2028
NCT07277413IDE892Phase 1NSCLC AdenocarcinomaOncologyApr 2028
NCT07174583IDE849Phase 1Small-cell Lung CancerOncologyJul 2029
NCT07174583IDE161Phase 1Small-cell Lung CancerOncologyJul 2029
NCT07540572IDE574Phase 1CancerOncologyDec 2029
NCT07015190DarovasertibPhase 3Uveal MelanomaOncologyOct 2030
NCT07804186DarovasertibPhase 3Uveal MelanomaOncologyMar 2034
NCT07804186CrizotinibPhase 3Uveal MelanomaOncologyMar 2034
NCT02201992CrizotinibPhase 3ALK Gene RearrangementOncologyMay 2036
NCT05725200CrizotinibPhase 2Metastatic Colorectal CancerOncologyDec 2038

From the company's SEC filings

Cash and short-term investments of $839m on 2026-09-30; operating cash outflow about $345m a year; runway about 29 months at that burn, to Mar 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PRKC (1) MET (1) ALK (1) EML4 (1) NPM1 (1) ROS1 (1) B7H3 (1) PTK7 (1) MAT2A (1) PRMT5 (1) KAT6 (1) KAT7 (1)

Companies with the same targets

Pfizer AstraZeneca Novartis Roche Johnson & Johnson (Janssen) Exelixis AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Turning Point Therapeutics Chia Tai Tianqing Pharmaceutical Group

Companies built like this

ArriVent BioPharma Servier Bio-Innovation Revolution Medicines MediLink Therapeutics (Suzhou) Cogent Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.